Dr. Nagesan Rajendran, MD

Dr. Rajendran practices at HSHS St. John's Hospital in Springfield, Illinois, part of Hospital Sisters of St. Francis.

Dr. Rajendran's NPI, 1497210694, was assigned on February 1, 2019. Dr. Rajendran holds Illinois license 036164209.

Dr. Rajendran's primary practice is HSHS St. John's Hospital, at 800 E Carpenter St, Springfield, IL 62769 in Sangamon County. The practice phone is (217) 544-6464.

Dr. Rajendran's primary practice is HSHS St. John's Hospital in Springfield, Illinois, part of Hospital Sisters of St. Francis. Dr. Rajendran is also affiliated with HSHS St. Anthony's Memorial Hospital. The medical group on file is Vituity (formerly CEP America). Dmand AI also links Dr. Rajendran to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rajendran practices, 5 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Rajendran's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dmand AI has Dr. Rajendran's licenses on file in 2 states: Illinois and Wisconsin.

CMS data shows 759 Medicare services from Dr. Rajendran across 6 procedure codes in 2024, for 213 Medicare patients. Medicare paid $45,828 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 213 Medicare patients who saw Dr. Rajendran in 2024. The largest group is 75 to 84, with 66 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rajendran's median patient age at 67, with 54% women.

In 2024, Dr. Rajendran wrote 330 Medicare Part D claims for 136 patients. 88% of them were for generic drugs. CMS names the drug for 132 of them, across 8 drugs with 11 or more claims each, at $13,074 in total drug cost. In 2023, CMS named 113 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Rajendran for performance year 2024, reported as part of a group. Dr. Rajendran accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 3 general payments to Dr. Rajendran from 3 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Alexion Pharmaceuticals, Inc. paid the most, $125.